Announcements Trials
Browse Landscape

Phase

Phase 1/2 4Phase 2 1

Status

Recruiting 5Completed 3Unknown 2Terminated 1

Sponsor Class

OTHER 3INDUSTRY 2

Study Type

Interventional 5

Sponsor

Cancer Type

Genitourinary 2Other solid neoplasm 1Gastrointestinal 1CNS 1

Conditions

Prostatic Neoplasms 2Pancreatic Neoplasms 1Malignant Solid Neoplasm 1Glioblastoma 1

Interventions

pembrolizumab 551Specimen Handling 465Carboplatin 441Magnetic Resonance Spectroscopy 430Cyclophosphamide 412Cisplatin 397Radiotherapy 313Gemcitabine 309Bevacizumab 307Paclitaxel 294Biopsy 261Drug Therapy 249Capecitabine 242Oxaliplatin 239fludarabine 237Nivolumab 224venetoclax 219Injections 213Docetaxel 205Fluorouracil 203Dexamethasone 187Radiosurgery 172Rituximab 158Pemetrexed 153Standard of Care 146durvalumab 143Leucovorin 139atezolizumab 138toripalimab 134tislelizumab 134

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Recruiting × Interventional × Verteporfin × Clear all
NCT03067051 2026-05-01

Clinical Study to Assess the Safety and Efficacy of the SpectraCure P18 System

SpectraCure AB

Phase 1/2 Recruiting
66 enrolled
Genitourinary

Prostatic Neoplasms

NCT06807359 2026-05-01

Photodynamic Therapy of Primary Localized Prostate Cancer With the SpectraCure P18 System

SpectraCure AB

Phase 1/2 Recruiting
43 enrolled
Genitourinary

Prostatic Neoplasms

NCT06306638 2026-04-06

Interstitial Photodynamic Therapy Following Palliative Radiotherapy in Treating Patients With Inoperable Malignant Central Airway Obstruction

Roswell Park Cancer Institute

Phase 1/2 Recruiting
42 enrolled
Other solid neoplasm

Malignant Solid Neoplasm

NCT06381154 2026-01-30

Photoradiation With Verteporfin to Facilitate Immunologic Activity of Pembrolizumab in Unresectable, Locally Advanced or Metastatic Pancreatic Cancer

Mayo Clinic

Phase 2 Recruiting
25 enrolled
Gastrointestinal

Pancreatic Neoplasms

NCT04590664 2025-02-25

Verteporfin for the Treatment of Recurrent High Grade EGFR-Mutated Glioblastoma

Emory University

Phase 1/2 Recruiting
24 enrolled
CNS

Glioblastoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡